Dnb.co.in

Pfizer limited
d&B d-U-n-s® no 65-005-2475
company Ranking
net Profit
net Worth
Background
company details
Pfizer Ltd (Pfizer) established its operations in India in 1950. The first production facility was set up at Darukhanna in Mumbai, where products like Protinex and Isonex were Business Operation
manufactured. In 1960, Pfizer began independent manufacturing of bulk drugs. The company Bulk drugs, formulations, vetinary products operates in three business segments namely pharmaceuticals, animal health and medical Chairperson
RA Shah
Managing Director
Business Profile
Pfizer’s pharmaceuticals division comprises manufacture and trade in bulk drugs and Directors
formulations. The animal health division has a presence primarily in animal health and poultry market segments. The medical and research division comprises clinical development Company Secretary
operations such as clinical trials, new product development and undertaking data management for new drug development. Pfizer operates a plant in Thane, Maharashtra Registered Office
producing non-sterile formulations of oral liquids, tablets and capsules. For the year ended Nov 30, 2006, pharmaceuticals contributed over 85% to total revenue, registering a y-o-y growth of over 10%. Pfizer is also present in the cardiovascular care segment through Healthy Heart, a disease management programme conducted in alliance with the Apollo Hospital Group. During 2006, Pfizer launched three global brands in India viz Viagra for erectile dysfunction; Lyrica for neuropathic pain and Caduet for hypertension associated with dyslipidemia. In 2007, Website
Pfizer Inc globally sold its consumer healthcare division to Johnson and Johnson. www.pfizerindia.com
Auditors
company Financials
alembic limited
d&B d-U-n-s® no 65-005-1741
company Ranking
net Profit
net Worth
In 2007, it bought Dabur Pharma’s 24 brands in lifestyle therapeutic segment Background
company details
Alembic Ltd (Alembic) was established in 1907 as Alembic Chemicals Works Co Ltd at Vadodara, Gujarat for manufacturing tinctures and alcohol. It entered the cough syrup, Business Operation
vitamins, tonics and sulphur drugs segment in 1940. It diversified into contract research business Apis, bulk drugs, chemicals, formulations in 2004. Alembic manufactures APIs, bulk drugs, formulations, herbal and veterinary medicines. Chairperson & MD
CR Amin
Business Profile
Directors
Alembic operates with two plants, each located in Gujarat and HP. The company primarily operates in two key areas of bulk drugs, APIs & chemicals and formulations. It manufactures branded and generic formulations for the therapeutic segments of antibiotic, cough & cold, Company Secretary
B-complex, pain, gastrointestinal. Company’s key brands include Glycodin, Nimegesic, Azithral and Zeet. The company introduced 25 new products in FY07. In FY07, the domestic Registered Office
formulation business grew 8%, whereas export formulation sales grew at 21%. The company is also involved in R&D activities of generic research, formulations research, contract research. In June 2006, the company merged its API & generics divisions into an international division for sale of APIs, formulation development, custom synthesis and Website
forming partnerships. In FY07, Alembic entered into a licensing agreement with the Brussels-based UCB for its NDDP for Keppra XR. Alembic entered the therapeutic segments of cardiovascular, diabetic by acquiring Dabur Pharma’s 24 brands.
Bankers
ABN, BoB, ICICI Bank, IDBI Bank, SBI, Axis Bank
Auditors
company Financials

Source: http://www.dnb.co.in/top500_08/Profile%5CPfizer%20Limited.pdf